Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.67 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.67 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987699 | 0.89 | AGTR1 (0.57) | AGTR1AGTR2PPARG | |
| SCHEMBL684085 | 0.87 | AGTR1 (0.71) | AGTR1AGTR2PPARG | |
| SCHEMBL12737295 | 0.87 | PPARG (0.64) | AGTR1AGTR2PPARG | |
| SCHEMBL5328080 | 0.86 | PPARG (0.61) | AGTR1AGTR2PPARG | |
| SCHEMBL7430230 | 0.86 | PPARG (0.63) | AGTR1AGTR2PPARG | |
| SCHEMBL8566093 | 0.84 | AGTR1 (0.68) | AGTR1AGTR2 | |
| SCHEMBL7312663 | 0.84 | AGTR1 (0.68) | AGTR1AGTR2PPARG | |
| SCHEMBL8207617 | 0.83 | PPARG (0.60) | AGTR1PPARG | |
| SCHEMBL12593005 | 0.83 | AGTR2 (0.74) | AGTR1AGTR2PPARG | |
| SCHEMBL7310636 | 0.83 | AGTR1 (0.66) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048904-B2 | Process for the preparation of olmesartan medoxomil | MATRIX LABORATORIES LTD. (IN) | 2011-11-01 | — | — | US | disclosed |
| US-20090281327-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| EP-0796852-B1 | Process for preparation of 5-substituted tetrazoles | TOYO KASEI KOGYO CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6040454-A | REACTING 1-(CYANOBIPHENYLMETHYL)IMIDAZOLE DERIVATIVE WITH AN ALKALI OR ALKALINE EARTH METAL AZIDE SALT IN AN AROMATIC HYDROCARBON SOLVENT IN PRESENCE OF AN AMINE SALT | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2000-03-21 | — | — | US | disclosed |
| CN-1045770-C | Process for preparing 1-biphenylmethylimidazole derivatives | SANKYO CO (JP) | 1999-10-20 | — | — | CN | disclosed |
| US-5744612-A | Process for preparation of 5- substituted tetrazoles | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 1998-04-28 | — | — | US | disclosed |
| EP-0796852-A1 | Process for preparation of 5-substituted tetrazoles | Toyo Kasei Kogyo Company Limited (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281327-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MED1, TET1, AGTR1 | AGTR1 3/4885AGTR2 5/4885PPARG 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.